Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.46 |
| ▸ | CTSD | P07339 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17655622 | 0.86 | BACE1 (0.46) | BACE1CTSDKCNH2 | |
| SCHEMBL15606015 | 0.85 | BACE1 (0.53) | BACE1CTSDKCNH2 | |
| SCHEMBL15606016 | 0.84 | BACE1 (0.47) | BACE1CTSDKCNH2 | |
| SCHEMBL15606179 | 0.77 | BACE1 (0.49) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL15605989 | 0.77 | BACE1 (0.35) | BACE1KCNH2 | |
| SCHEMBL17655623 | 0.77 | BACE1 (0.35) | BACE1KCNH2 | |
| SCHEMBL16663951 | 0.76 | BACE1 (0.47) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL429328 | 0.76 | BACE1 (0.62) | BACE1CTSDAPP | |
| SCHEMBL15606038 | 0.71 | BACE1 (0.36) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL15606014 | 0.71 | BACE1 (0.34) | BACE1CTSDKCNH2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233982-B2 | Spiro tetrahydro—benzothiophen derivatives useful for the treatment neurodegenerative diseases | ARES TRADING S.A. (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | ARES TRADING S.A. (CH) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111882-A1 | SPIRO TETRAHYDRO - BENZOTHIOPHEN DERIVATIVES USEFUL FOR THE TREATMENT NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, BACE2 | BACE1 4/4885CTSD 1626/4885KCNH2 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.